JPH04501719A - ポリペプチド - Google Patents

ポリペプチド

Info

Publication number
JPH04501719A
JPH04501719A JP1511698A JP51169889A JPH04501719A JP H04501719 A JPH04501719 A JP H04501719A JP 1511698 A JP1511698 A JP 1511698A JP 51169889 A JP51169889 A JP 51169889A JP H04501719 A JPH04501719 A JP H04501719A
Authority
JP
Japan
Prior art keywords
item
items
cells
polypeptide
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP1511698A
Other languages
English (en)
Japanese (ja)
Inventor
テイラー―パパデイミトリオウ，ジヨイス
ジエンドラー，サンドラ
バーチエル，ジヨイ
Original Assignee
インペリアル・キヤンサー・リサーチ・テクノロジー・リミテツド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB888826362A external-priority patent/GB8826362D0/en
Priority claimed from GB898907660A external-priority patent/GB8907660D0/en
Application filed by インペリアル・キヤンサー・リサーチ・テクノロジー・リミテツド filed Critical インペリアル・キヤンサー・リサーチ・テクノロジー・リミテツド
Publication of JPH04501719A publication Critical patent/JPH04501719A/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4727—Mucins, e.g. human intestinal mucin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP1511698A 1988-11-10 1989-11-10 ポリペプチド Pending JPH04501719A (ja)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB8826362.9 1988-11-10
GB888826362A GB8826362D0 (en) 1988-11-10 1988-11-10 Polypeptide
GB8907660.8 1989-04-05
GB898907660A GB8907660D0 (en) 1989-04-05 1989-04-05 Polypeptide

Publications (1)

Publication Number Publication Date
JPH04501719A true JPH04501719A (ja) 1992-03-26

Family

ID=26294608

Family Applications (1)

Application Number Title Priority Date Filing Date
JP1511698A Pending JPH04501719A (ja) 1988-11-10 1989-11-10 ポリペプチド

Country Status (3)

Country Link
EP (1) EP0442926A1 (fr)
JP (1) JPH04501719A (fr)
WO (1) WO1990005142A1 (fr)

Families Citing this family (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1339204C (fr) * 1987-01-07 1997-08-05 Joyce Taylor-Papadimitriou Polypeptides, anticorps et sondes a noyau de mucine
US6054438A (en) * 1987-01-07 2000-04-25 Imperial Cancer Research Technology Limited Nucleic acid fragments encoding portions of the core protein of the human mammary epithelial mucin
GB8929097D0 (en) * 1989-12-22 1990-02-28 Imp Cancer Res Tech Mucin nucleotides
GB9019553D0 (en) * 1990-09-07 1990-10-24 Unilever Plc Specific binding agents
FR2668064B1 (fr) * 1990-10-23 1994-12-16 Transgene Sa Composition pharmaceutique pour le traitement ou la prevention d'une tumeur maligne.
GB9108652D0 (en) * 1991-04-23 1991-06-12 Antisoma Ltd Immunoreactive compounds
JP3698370B2 (ja) * 1992-04-13 2005-09-21 ダナ−ファーバー キャンサー インスティチュート インク 癌腫抗原用抗体
WO1994011508A2 (fr) * 1992-11-13 1994-05-26 Cancer Research Fund Of Contra Costa Polypeptides presentant une specificite par rapport aux neoplasies, kit et procedes diagnostiques, therapeutiques et de vaccination
AUPM322393A0 (en) * 1993-12-24 1994-01-27 Austin Research Institute, The Mucin carbohydrate compounds and their use in immunotherapy
AU2247095A (en) * 1994-04-12 1995-10-30 Biomira Inc. Cellular immune response-specific antigens and uses therefor
US5827498A (en) * 1994-06-07 1998-10-27 Nihon Medi-Physics Co., Ltd. Tumor affinity peptide, and radioactive diagnostic agent and radioactive therapeutic agent containing the peptide
US8021667B2 (en) 1994-11-16 2011-09-20 Macfarlane Burnet Institute For Medical Research And Public Health Ltd Compositions for immunotherapy and uses thereof
US6548643B1 (en) * 1994-11-16 2003-04-15 Austin Research Institute Antigen carbohydrate compounds and their use in immunotherapy
AU2540897A (en) * 1996-03-21 1997-10-10 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Methods and compositions of chimeric polypeptides for tumor antigen vaccines
GB9717946D0 (en) * 1997-08-22 1997-10-29 Imp Cancer Res Tech Novel chemical entity
EP1027063B1 (fr) 1997-09-29 2009-02-18 The Macfarlane Burnet Institute For Medical Research And Public Health Ltd Composition d'antigene et de cellules portant des recepteurs de mannose
EP1369428A1 (fr) * 1997-10-31 2003-12-10 Biomira Inc. Dérivés de Muc-1 et leur utilisation dans le traitement d'immunosupression induite par le MUC-1 Mucin associé au cancer
EP1027373B1 (fr) * 1997-10-31 2006-09-06 Biomira, Inc. Derives de muc-1 et leur utilisation pour traiter l'immunodepression induite par la mucine muc-1 et associee au cancer
US20080050367A1 (en) 1998-04-07 2008-02-28 Guriq Basi Humanized antibodies that recognize beta amyloid peptide
US7964192B1 (en) 1997-12-02 2011-06-21 Janssen Alzheimer Immunotherapy Prevention and treatment of amyloidgenic disease
TWI239847B (en) 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
DE19758400A1 (de) * 1997-12-30 1999-07-01 Max Delbrueck Centrum Tumorvakzine für MUC1-positive Karzinome
MY139983A (en) 2002-03-12 2009-11-30 Janssen Alzheimer Immunotherap Humanized antibodies that recognize beta amyloid peptide
US7858367B2 (en) 2002-04-30 2010-12-28 Duke University Viral vectors and methods for producing and using the same
EP1838348B1 (fr) 2004-12-15 2013-06-26 Janssen Alzheimer Immunotherapy Anticorps du peptide beta-amyloide humanises utilises dans l'amelioration de la cognition
US8784810B2 (en) 2006-04-18 2014-07-22 Janssen Alzheimer Immunotherapy Treatment of amyloidogenic diseases
US8003097B2 (en) 2007-04-18 2011-08-23 Janssen Alzheimer Immunotherapy Treatment of cerebral amyloid angiopathy
DK2182983T3 (da) 2007-07-27 2014-07-14 Janssen Alzheimer Immunotherap Behandling af amyloidogene sygdomme med humaniserede anti-abeta antistoffer
JO3076B1 (ar) 2007-10-17 2017-03-15 Janssen Alzheimer Immunotherap نظم العلاج المناعي المعتمد على حالة apoe
US9067981B1 (en) 2008-10-30 2015-06-30 Janssen Sciences Ireland Uc Hybrid amyloid-beta antibodies
WO2010093784A2 (fr) 2009-02-11 2010-08-19 The University Of North Carolina At Chapel Hill Vecteurs viraux modifiés et procédés de fabrication et d'utilisation de ceux-ci
EP2524037B1 (fr) 2010-01-12 2018-05-16 The University Of North Carolina At Chapel Hill Répétitions terminales inversées restrictives pour vecteurs viraux
WO2012109570A1 (fr) 2011-02-10 2012-08-16 The University Of North Carolina At Chapel Hill Vecteurs viraux à profil de transduction modifiée et procédés pour les préparer et les utiliser
EP2900686B1 (fr) 2012-09-28 2020-06-10 The University of North Carolina At Chapel Hill Vecteurs vaa ciblés sur des oligodendrocytes
ES2926774T3 (es) 2013-03-15 2022-10-28 Univ North Carolina Chapel Hill Métodos y composiciones para vectores AAV de doble unión de glicano
WO2014143932A1 (fr) 2013-03-15 2014-09-18 The University Of North Carolina At Chapel Hill Répétitions terminales inversées de synthèse du virus adéno-associé
EP4344741A3 (fr) 2014-11-21 2024-08-28 The University of North Carolina at Chapel Hill Vecteurs aav ciblant le système nerveux central
US10907176B2 (en) 2015-01-14 2021-02-02 The University Of North Carolina At Chapel Hill Methods and compositions for targeted gene transfer
MX388739B (es) 2015-02-06 2025-03-20 Univ North Carolina Chapel Hill Casetes optimizados de expresión del gen humano del factor viii de coagulación y su uso.
HK1248554A1 (zh) 2015-02-20 2018-10-19 Board Of Regents, The University Of Texas System 作为疫苗和载体的减毒衣原体的方法和组合物
ES2865487T3 (es) 2015-09-28 2021-10-15 Univ North Carolina Chapel Hill Métodos y composiciones para vectores virales que evaden los anticuerpos
US10801041B2 (en) 2015-11-18 2020-10-13 Orbis Health Solutions, Llc T7 alpha viral vector system
JP7406783B2 (ja) 2015-12-14 2023-12-28 ザ ユニバーシティ オブ ノース カロライナ アット チャペル ヒル パルボウイルスベクターの高められた送達のための改変キャプシドタンパク質
NZ756587A (en) 2017-03-15 2025-12-19 Univ North Carolina Chapel Hill Polyploid adeno-associated virus vectors and methods of making and using the same
EP3759218A4 (fr) 2018-02-28 2021-12-08 The University of North Carolina at Chapel Hill Méthodes et compositions pour vecteurs viraux évitant les anticorps
AU2019247748A1 (en) 2018-04-03 2020-10-08 Ginkgo Bioworks, Inc. Antibody-evading virus vectors
EP3774852A1 (fr) 2018-04-03 2021-02-17 Stridebio, Inc. Vecteurs viraux évitant les anticorps
MX2020010465A (es) 2018-04-03 2021-01-08 Vectores de virus para direccionamiento a tejidos oftalmicos.
AU2019287468B2 (en) 2018-06-12 2024-10-10 The University Of North Carolina At Chapel Hill Synthetic liver-tropic adeno-associated virus capsids and uses thereof
EP3810782A2 (fr) 2018-06-22 2021-04-28 Asklepios Biopharmaceutical, Inc. Vecteurs pour l'administration de gènes qui persistent dans les cellules
AR118465A1 (es) 2019-03-21 2021-10-06 Stridebio Inc Vectores de virus adenoasociados recombinantes
EP4169535A1 (fr) 2019-04-26 2023-04-26 The University of North Carolina at Chapel Hill Procédés et compositions de double liaison glycane de vecteurs de vaa2.5
US12611436B2 (en) 2019-10-17 2026-04-28 Sarepta Therapeutics, Inc. AAV transfer cassette
JP2022551739A (ja) 2019-10-17 2022-12-13 ストライドバイオ，インコーポレイテッド ニーマン・ピック病ｃ型の治療のためのアデノ随伴ウイルスベクター
JP2023524577A (ja) 2020-05-05 2023-06-12 ザ・ユニヴァーシティ・オヴ・ノース・キャロライナ・アト・チャペル・ヒル 改変アデノ随伴ウイルス５カプシドおよびその使用
AU2021328475A1 (en) 2020-08-19 2023-03-16 Sarepta Therapeutics, Inc. Adeno-associated virus vectors for treatment of Rett syndrome
WO2022093769A1 (fr) 2020-10-28 2022-05-05 The University Of North Carolina At Chapel Hill Procédés et compositions de double liaison glycane de vecteurs de vaa2.5
CN116490514A (zh) 2020-10-28 2023-07-25 北卡罗来纳-查佩尔山大学 用于双重聚糖结合aav2.5载体的方法和组合物
TW202242124A (zh) 2021-01-14 2022-11-01 美商史崔德生物公司 靶向ｔ細胞之ａａｖ載體
WO2022221529A1 (fr) 2021-04-16 2022-10-20 Asklepios Biopharmaceutical, Inc. Virions de vaa à polyploïde rationnel traversant la barrière hémato-encéphalique et déclenchant une réponse humorale réduite
TW202342759A (zh) 2022-02-04 2023-11-01 美商史崔德生物公司 重組腺相關病毒載體及其使用方法
WO2024124019A2 (fr) 2022-12-07 2024-06-13 Ginkgo Bioworks, Inc. Vecteurs aav ciblant des cellules souches hématopoïétiques
CN121889172A (zh) 2023-07-21 2026-04-17 意大利商博雷亚医疗有限责任公司 制备表面修饰病毒衣壳的方法

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1339204C (fr) * 1987-01-07 1997-08-05 Joyce Taylor-Papadimitriou Polypeptides, anticorps et sondes a noyau de mucine

Also Published As

Publication number Publication date
WO1990005142A1 (fr) 1990-05-17
EP0442926A1 (fr) 1991-08-28

Similar Documents

Publication Publication Date Title
JPH04501719A (ja) ポリペプチド
US12338272B2 (en) High avidity antigen recognizing constructs
US6344203B1 (en) Mimicking peptides in cancer therapy
ES2240981T3 (es) Citocina denominada lerk-7.
ES2652017T3 (es) Métodos y composiciones farmacéuticas para el engaño inmunitario, particularmente útiles en el tratamiento de cáncer
US9452204B2 (en) Chimeric peptides comprising HER-2 B-cell epitopes and Tcell helper epitopes
US7268207B2 (en) Gene differentially expressed in breast and bladder cancer, and encoded polypeptides
EA030777B1 (ru) Анти-альфа-синуклеинсвязывающие молекулы
JPH09505723A (ja) ４３ｋｄヒトガン抗原からの免疫反応性ペプチド配列
US7358087B2 (en) Compositions and methods for enhancing immune responses mediated by antigen-presenting cells
JP2021521817A5 (fr)
WO2011091716A1 (fr) Variante du récepteur du facteur de croissance épidermique
CN111378039A (zh) 治疗恶性肿瘤的抗体及其应用
Liang et al. Antibody binding to a peptide but not the whole protein by recognition of the C-terminal carboxy group
CN1082053A (zh) 合成多肽
EP1167387A1 (fr) Anticorps anti-SEMP1, procédé pour leur production, et leurs utilisations
US20050063970A1 (en) Methods and pharmaceutical compositions for immune deception, particularly useful in the treatment of cancer
US20240182577A1 (en) Anti-pd-1 signal peptide antibody and use thereof
CN103539840B (zh) 表皮生长因子受体模拟表位肽及其应用
CN102127147B (zh) 表皮生长因子受体模拟表位肽及其应用
JP2005513040A (ja) Ｔｌｐペプチドを含む融合タンパク質
Xing et al. Peptide epitopes in breast cancer mucins
JP4037451B2 (ja) 大腸細胞および大腸癌細胞関連核酸分子、タンパク質およびペプチド
WO2004022589A9 (fr) Marqueur tumoral et ses applications
WO2000020442A1 (fr) Peptides antigenes specifiques aux tumeurs